J Clin Oncol 2022 Jan 07
Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).
Abstract
Purpose
Distant metastases are present in 6% or more of patients with newly diagnosed breast cancer. In this context, locoregional therapy for the intact primary tumor has been hypothesized to improve overall survival (OS), but clinical trials have reported conflicting results.
Methods
Women presenting with metastatic breast cancer and an intact primary tumor received systemic therapy for 4-8 months; if no disease progression occurred, they were randomly assigned to locoregional therapy for the primary site (surgery and radiotherapy per standards for nonmetastatic disease) or continuing sysmetic therapy. The primary end point was OS; locoregional control and quality of life were secondary end points. The trial design provided 85% power to detect a 19.3% absolute difference in the 3-year OS rate in randomly assigned patients. The stratified log-rank test and Cox proportional hazards model were used to compare OS between arms. Cumulative incidence of locoregional progression was compared using Gray's test. Quality-of-life assessment used standard instruments.
Results
Of 390 participants enrolled, 256 were randomly assigned: 131 to continued systemic therapy and 125 to early locoregional therapy. The 3-year OS was 67.9% without and 68.4% with early locoregional therapy (hazard ratio = 1.11; 90% CI, 0.82 to 1.52; P = .57). The median OS was 53.1 months (95% CI, 47.9 to not estimable) in the systemic therapy arm and 54.9 months (95% CI, 46.7 to not estimable) in the locoregional therapy arm. Locoregional progression was less frequent in those randomly assigned to locoregional therapy (3-year rate: 16.3% v 39.8%; P < .001). Quality-of-life measures were largely similar between arms.
Conclusion
Early locoregional therapy for the primary site did not improve survival in patients presenting with metastatic breast cancer. Although it was associated with improved locoregional control, this had no overall impact on quality of life.
Related Questions
Do you offer consolidative radiation for oligometastatic breast cancer?
I'd like to add a few additional considerations to the already excellent responses from our colleagues. Many of the trials cited actually address two related but distinct clinical questions, and the answer for HER2-positive disease specifically may diverge from the population-level results.Trials of...
What is the current paradigm for breast cancer diagnosed with isolated metastases prior to initial treatment?
Surgery of the primary did not significantly improve overall survival in which patients were randomly allocated to receive systemic therapy alone or (for responding patients) to systemic therapy followed by primary tumor resection in the trial conducted by ECOG-ACRIN (Khan et al., PMID 34995128), at...
In which scenarios do you stage breast cancer using CT and nuclear bone scans versus PET-CT?
In a recent study (Dayes et al., PMID 37235845), systemic staging with FDG PET-CT more frequently changed the clinical stage from IIB or III breast cancer to stage IV disease (23% metastases detection rate) than staging with CTs of the chest, abdomen, pelvis, and a bone scan combined (11% metastases...
What are your top takeaways in Breast Cancer from ASCO 2023?
SONIA: A notable trial comparing CDK4/6 inhibitors as 1st line vs. 2nd line treatment. AI+CDKi combination therapy as 1st line does not improve OS, 2nd PFS, or QOL compared to combination therapy as 2nd line. Factors such as the site of metastasis, tumor burden, symptoms, cost, and side effects sho...
Would you offer definitive local therapy to a patient with ER/PR+, Her2 neg breast cancer with oligometastatic disease that responded well to CDK 4/6 inhibitor +AI, despite NRG-BR002 results?
The description of "ER/PR positive HER2 negative right breast cancer with a synchronous single site of oligo-metastatic disease in the right 4th rib (near primary tumor but not clearly direct extension) and good response to 6 months of AI+CDK4i" suggests that the primary breast cancer is intact. The...
How would you approach a young patient with oligometastatic inflammatory triple negative breast cancer with bone only metastases?
There is no clinical trial data to provide solid guidance on how to manage oligometastatic de novo stage IV disease. We learned that surgery to the primary tumor without ablating distant mets and giving multidrug adjuvant-like systemic therapy does not improve survival. We also learned that SBRT to ...
Would you offer PMRT to ER/PR+ patients with synchronous bone metastasis?
This is a more common scenario despite data suggesting a local survival benefit with the addition of local therapy to patients with metastatic breast cancer. With synchronous bone mets- we usually start with systemic therapy, ER+ would be endocrine therapy + CDK 4/6 inhibitor commonly. If stable/res...
Do you ever consider local therapy to oligometastatic hormone-receptor positive breast cancer?
Surgery or radiation therapy in metastatic breast cancer patient is one of hot topics in care of the patients with stage IV disease, especially since the survival of oligometastatic breast cancer and widely spread metastatic breast cancer is vastly different. For instance, the 5 year survival of oli...